Pacific Bio (PACB) Q3 Revenue Misses Estimates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Piper Jaffray Upgrades Pacific Biosciences of California (PACB) to Overweight
October 23, 2015 7:09 AM EDTPiper Jaffray upgraded Pacific Biosciences of California (NASDAQ: PACB) from Neutral to Overweight with a price target of $9.00 (from $7.00).
Analyst William R. Quirk commented, "Pacific Biosciences reported 3Q15 revenue of $13.9M, below our $16.4M estimate and the Street's $15.8M expectations. Ongoing... More
